Hexiris Ophthalmics, a Canadian ophthalmic device company developing technologies to expand access to interventional glaucoma care, announced a series of milestones that mark progress toward the commercial launch of its first products later in 2026.

The company’s presented scientific presentations at two international ophthalmology congresses, launched its corporate website and social media channels, continued momentum in its surgeon engagement program, and announced upcoming participation at the Canadian Ophthalmological Society (COS) annual meeting in Montreal, where surgeons will be invited to experience the company’s OBi platform through a hands-on dry lab.

At the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, Paul Harasymowycz, MD, FRCSC, presented data on office-based slit-lamp interventional glaucoma surgery. At the Mexican Society of Ophthalmology Meeting, José Ramón Ponce Martínez, MD, presented clinical experience with the same approach in a presentation titled: “Cirugía del Glaucoma Intervencional con Lámpara de Hendidura en el Consultorio.”

“Expanding access to interventional glaucoma is why Hexiris Ophthalmics exists,” said Dr. Houfar Sekhavat, Co-Founder of Hexiris Ophthalmics. “Too many patients who need treatment cannot get it, not because the surgery is unavailable, but because the settings in which it can be performed are out of reach. We are building the tools to change that, and we are genuinely excited to be moving closer to putting them in surgeons’ hands.”

Hexiris Ophthalmics will exhibit at the Canadian Ophthalmological Society (COS) annual meeting in Montreal this June. During the meeting, attending surgeons will have the opportunity to gain first-hand experience with OBi Core and OBi Gon through dedicated hands-on, in-booth dry lab sessions.

The sessions will provide participants with an opportunity to evaluate the company’s approach to office-based interventional glaucoma procedures and interact directly with the technology ahead of commercial launch. Space for the dry lab experience is limited, and pre-registration is encouraged. The devices featured are Health Canada approved and FDA registered.

The company has also introduced "Expanding Access," a quarterly newsletter designed to keep surgeons, industry partners, and investors informed about advances in interventional glaucoma care, clinical developments, and company milestones.